Botox maker Allergan plc has agreed to acquire Kythera Biopharmaceuticals Inc. for about $2.1 billion in cash and stock, the two companies said Wednesday. Kythera is a developer of prescription products for the aesthetic medicine market. Kythera’s lead product, Kybella, is the first and only approved non-surgical treatment for reduction of submental fullness, or double chin.